ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $139 | -12.6% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $159 | -74.5% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $623 | -37.7% | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | -33.3% | 100 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $3,000 | -25.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $5,000 | -16.7% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | +50.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $5,000 | -28.6% | 100 | 0.0% | 0.00% | -33.3% |
| Q1 2018 | $7,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |